RE-LY: NSAIDs Plus Anticoagulants a Dangerous Combination RE-LY: NSAIDs Plus Anticoagulants a Dangerous Combination

The authors caution against using an NSAID with oral anticoagulants in patients with atrial fibrillation after finding an increased risk for bleeding and stroke.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news

Related Links:

ConclusionsART-CAF evaluates the feasibility of selecting high-risk patients suitable for anticoagulation by AF burden combined with CHA2DS2-VASc score after pacemaker implantation and aims to select patients who could benefit from anticoagulation.Trial Registration ChiCTR1800016221
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
CONCLUSIONS: This is the most extensive systematic review of RCTs conducted to date to assess effects of increasing PUFA on cardiovascular disease, mortality, lipids or adiposity. Increasing PUFA intake probably slightly reduces risk of coronary heart disease and cardiovascular disease events, may slightly reduce risk of coronary heart disease mortality and stroke (though not ruling out harms), but has little or no effect on all-cause or cardiovascular disease mortality. The mechanism may be via lipid reduction, but increasing PUFA probably slightly increases weight. PMID: 30019767 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Non valvular atrial fibrillation (NVAF) is highly prevalent among chronic kidney disease (CKD) patients in whom it portends increased risk for subsequent stroke or systemic thromboembolic events. For these high risk patients oral anticoagulation is recommended, after proper assessment of both thromboembolic and bleeding risk is accurately ascertained.However, current NVAF risk scores are inadequate for use in CKD subjects, since they do not take into account the occurrence and the degree of renal function impairment.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Abstract BACKGROUND AND OBJECTIVES: All randomized trials of direct oral anticoagulants in atrial fibrillation excluded patients with severe kidney disease. The safety and effectiveness of direct oral anticoagulants across the range of eGFR in real-world settings is unknown. Our objective is to quantify the risk of bleeding and benefit of ischemic stroke prevention for direct oral anticoagulants compared with warfarin in patients with atrial fibrillation with and without CKD. DESIGN, SETTING, PARTICIPANTS, &MEASUREMENTS: We created a propensity score-matched cohort of 3206 patients with atrial fibrillatio...
Source: Clinical Journal of the American Society of Nephrology : CJASN - Category: Urology & Nephrology Authors: Tags: Clin J Am Soc Nephrol Source Type: research
The authors caution against using an NSAID with oral anticoagulants in patients with atrial fibrillation after finding an increased risk for bleeding and stroke.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Publication date: March 2018Source: Advances in Medical Sciences, Volume 63, Issue 1Author(s): Ewelina Michniewicz, Elżbieta Mlodawska, Paulina Lopatowska, Anna Tomaszuk-Kazberuk, Jolanta MalyszkoAbstractCoronary artery disease (CAD) is the most common cardiovascular disease while atrial fibrillation (AF) is the most common cardiac arrhythmia. Both diseases share associated risk factors – hypertension, diabetes mellitus, sleep apnea, obesity and smoking. Moreover, inflammation plays a causative role in both diseases. The prevalence of CAD in patients with AF is from 17% to 46.5% while the prevalence of AF among pati...
Source: Advances in Medical Sciences - Category: Biomedical Science Source Type: research
This study is registered with, number NCT02513316.FindingsBetween Aug 4, 2011, and July 31, 2015, we recruited 1490 participants of whom follow-up data were available for 1447 (97%), over a mean period of 850 days (SD 373; 3366 patient-years). The symptomatic intracranial haemorrhage rate in patients with cerebral microbleeds was 9·8 per 1000 patient-years (95% CI 4·0–20·3) compared with 2·6 per 1000 patient-years (95% CI 1·1–5·4) in those without cerebral microbleeds (adjusted hazard ratio 3·67, 95% CI 1·27–10·60). Compared...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: Available online 27 June 2018Source: Revista Española de Cardiología (English Edition)Author(s): Maria Mahmood, Gregory Y.H. LipAbstractBoth atrial fibrillation (AF) and chronic kidney disease (CKD) are highly prevalent, especially with increasing age and associated comorbidities, such as hypertension, diabetes, heart failure, and vascular disease. The relationship between both AF and CKD seems to be bidirectional: CKD predisposes to AF while onset of AF seems to lead to progression of CKD. Stroke prevention is the cornerstone of AF management, and AF patients with CKD are at higher risk of ...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
ConclusionsCardiovascular event rate one year after electrical cardioversion was low. Electrical cardioversion had a high immediate success rate, however, maintenance of stable sinus rhythm in the long term was low.
Source: Cor et Vasa - Category: Cardiology Source Type: research
ConclusionsA bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Health | Heart | Stroke